The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials

Figures & data

Figure 1 Eligibility of studies for inclusion in meta-analysis.

Abbreviation: RCT, randomized controlled trial.

Table 1 Baseline characteristics of patients in the trials included in the meta-analysis

Study	Country	Treatment regimen	Duration (weeks)	No	Male/female	Age (mean ± SD, years)	Jadad score
Baldwin et al^Citation21	Non-US	Vortioxetine 10 mg/day	8	151	51/100	45.2±13.1	4
		Placebo		145	45/103	43.4±12.5
Henigsberg et al^Citation22	Non-US	Vortioxetine 10 mg/day	8	140	55/85	46.4±12.3	4
		Placebo		140	54/86	46.4±12.3
Jacobsen et al^Citation23	US	Vortioxetine 10 mg/day	8	155	37/118	43.1±12.0	4
		Placebo		157	47/110	42.3±11.6
Mahableshwarkar et al^Citation24	US	Vortioxetine 10 mg/day	8	157	44/113	45.2±11.9	5
		Placebo		160	52/108	46.2±11.8
Alvarez et al^Citation25	Non-US	Vortioxetine 10 mg/day	6	100	34/66	43.3±13.1	4
		Placebo		105	36/69	42.0±10.9
McIntyre et al^Citation26	USA, non-US	Vortioxetine 10 mg/day	8	195	61/134	45.4±12.2	5
		Placebo		196	67/129	45.6±12.1

Abbreviation: SD, standard deviation.

Figure 2 Forest plot showing the effect of 10 mg vortioxetine on the response rate and remission rate.

Abbreviations: RR, risk ratio; CI, confidence interval.

Figure 3 Forest plot showing the effect of 10 mg vortioxetine on the MADRS score.

Note: Weights are from random effects analysis.
Abbreviations: WMD, weighted mean difference; CI, confidence interval; MADRS, Montgomery–Asberg Depression Rating Scale.

Figure 4 Forest plot showing the effect of 10 mg vortioxetine on the HAM-D₂₄, CGI-S, and CGI-I scores.

Note: Weights are from random effects analysis.
Abbreviations: WMD, weighted mean difference; CI, confidence interval; HAM-D₂₄, Hamilton Rating Scale for Depression (24-items); CGI-S, Clinical Global Impression-Severity; CGI-I, Clinical Global Impression-Improvement.

Table 2 Summary of RR of adverse events in patients with major depressive disorder

Adverse events	RR	95% CI	P-value
Nausea	3.44	2.63–4.48	<0.001
Vomiting	2.78	1.32–5.85	0.007
Constipation	2.03	1.15–3.58	0.015
Hyperhidrosis	4.44	1.29–15.26	0.018
Headache	0.97	0.76–1.22	0.766
Diarrhea	1.17	0.78–1.77	0.458
Dizziness	0.92	0.61–1.39	0.708
Dry mouth	1.04	0.70–1.55	0.840
Fatigue	1.02	0.54–1.92	0.961
Insomnia	0.83	0.35–1.95	0.662
Nasopharyngitis	0.62	0.32–1.18	0.142

Abbreviations: RR, risk ratio; CI, confidence interval.

BaldwinDSLoftHDragheimMA randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)Eur Neuropsychopharmacol20122248249122209361

 PubMed Web of Science ®Google Scholar

HenigsbergNMahableshwarkarARJacobsenPA randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorderJ Clin Psychiatry20127395395922901346

 PubMed Web of Science ®Google Scholar

JacobsenPLMahableshwarkarARSerenkoMA randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorderJ Clin Psychiatry20157657558226035185

 PubMed Web of Science ®Google Scholar

MahableshwarkarARJacobsenPLSerenkoMA randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorderJ Clin Psychiatry20157658359126035186

 PubMed Web of Science ®Google Scholar

AlvarezEPerezVDragheimMA double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInt J Neuropsychopharmacol20121558960021767441

 PubMed Web of Science ®Google Scholar

McIntyreRSLophavenSOlsenCKA randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adultsInt J Neuropsychopharmacol2014171557156724787143

 PubMed Web of Science ®Google Scholar